As of June 19, 2025, Deciphera Pharmaceuticals Inc (DCPH) reports a Net Margin of -119.34%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Deciphera Pharmaceuticals Inc's Net Margin
Over recent years, Deciphera Pharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2023-12-31 | -119.34% |
| 2022-12-31 | -133.49% |
| 2021-12-31 | -311.98% |
| 2020-12-31 | -633.19% |
| 2019-12-31 | -769.02% |
This steady improvement highlights how Deciphera Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Deciphera Pharmaceuticals Inc's Net Margin to Peers
To better understand Deciphera Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Deciphera Pharmaceuticals Inc (DCPH) | -119.34% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
| Ligand Pharmaceuticals Inc (LGND) | -2.41% |
Compared to its competitors, Deciphera Pharmaceuticals Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.